Expert Interview
Discussing the AstraZenaca's B7-H4–targeting topoisomerase 1 inhibitor antibody-drug conjugate, puxitatug samrotecan (AZD8205), and the results from the phase 1/2a BLUESTAR study in endometrial cancer presented at the 2025 SGO Meeting.
Ticker(s): AZNGynecologic Oncology, Gynecologic cancers (cervical, ovarian, uterine, endometrial, etc.) Rare gynecologic cancers (sarcoma, germ cell, stromal, PARP inhibitor
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
